As reported earlier Siga Technologies filed a patent application in the USA describing cyclodextrin solubilized tecovirimat (ST-246). Tecovirimat has low solubility in water (<0.1 mg/mL) and in pharmaceutically acceptable pH buffers creates an impediment to making safe and effective ST-246 liquid formulations.  EMA authorized the use of the drug tecovirimat as an oral medicine to treat smallpox, monkeypox and cowpox, three infections caused by viruses belonging to the same family (orthopoxviruses). 
Siga’s TPOXX (tecovirimat) injection, for intravenous use has been very recently approved by FDA, on May 19, 2022.  The product is a single-dose vial containing 200 mg of tecovirimat in 20 mL for further dilution prior to intravenous infusion. 8 g dose of hydroxypropyl-β-cyclodextrin (per 200 mg tecovirimat/20 mL solution) is applied to solubilize the drug. The product contains only Hydroxypropyl Betadex, NF (hydroxypropyl β-cyclodextrin) and Water for Injection, USP/NF besides the active pharmaceutical ingredient.  In the moment the product is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.